Antiphospholipid syndrome: Clinical manifestations and management

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 27-30

  Greaves, M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CHLORPROMAZINE; IMMUNOSUPPRESSIVE AGENT; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC TEST; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; PREGNANCY DISORDER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; DISEASE MANAGEMENT; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 12544255660     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-53.
2. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-8.
3. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clinic Proc 1999;74:275-284.
4. Asherson RA, Cervera R, Piette J-C, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, Ingelmo M. Catastrophic antiphospholipid syndrome: Clinical and laboratory features in 50 patients. Medicine 1999;77:195-207.
5. Al-Saeed A, Makris M, Malia RG, Preston FE, Greaves M. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C Brit J Haematol 1994;58:18-23.
6. de Larranaga GF, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariksian G, Sturmo MM, Alonso BS. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus 2000;9:594-600.
7. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
8. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-7.
9. Jennings I, Woods TAL, Kitchen S, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of the results from the surveys of the UK national external quality assurance scheme (NEQAS) in blood coagulation. Thromb Haemost 1997;77:810-1.
10. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TAL, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Brit J Haem 2002;119:364-9.
11. Le Querrec A, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, Delahousse B, Sie P. Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and antiprothrombin monoclonal antibodies. Thromb Haemost 2001;86:584-9.
12. Tripodi A, Biasiolo A, Chanarangkul V, Pengo V. Lupus anticoagulant testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003;49:1608-14.
13. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmario M, Potron G. Multicentre evaluation of nine commercial kits for the quantification of antiphospholipid antibodies. Thromb Haemost 1995;73:444-52.
14. Favaloro EJ, Sivestrini R. Assessing the usefulness of anticardiolipin assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002;118:548-57.
15. Galli M, Finazzi J, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombindependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995;86:617-23.
16. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. Beta2-glycoprotein 1 dependent lupus anticoagulant highly correlates with thrombosis in the Antiphospholipid Syndrome. Blood 2004-03-1107. Online August 17.
17. Simmelink MJ, Derksen RH, Arnout J, de Groot PG. A simple method to discriminate between beta2-glycoprotein 1- and prothrombindependent lupus anticoagulants. J Thromb Haemost 2003;1:740-7.
18. Horbach D, Van Oort E, Donders RC, Derksen RH, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with SLE-comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
19. Wahl DG, Guillemin F, De Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in SLE - A meta-analysis. Lupus 1997;6:467-73.
20. Cabides J, Cabral A, Alarcon-Segovia D. Clinical manifestations of antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti beta2 glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-1906.
21. McNally T, Mackie IJ, Machin SJ, Isenburg DA. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Brit J Rheumatol 1995;34:1031-6.
22. Previtali S, Barbui T, Galli M. (2002) Anti-beta 2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002;88:729-32.
23. Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P. Distinguishing features of anti-beta 2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 2002;87:599-605.
24. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. New Eng J Med 1995;332:993-7.
25. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New Eng J Med 2003;49:1133-8.
26. van Goor MPJ, Alblas CL, Leebeek FWG, Koudstaal PJ, Dippel DWJ. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurologica Scand 2004;109:410-5.
27. The APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.